The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.126.11.1647

The authors studied 500 psychiatric patients who had been treated polypharmaceutically. The group was divided into thirds—one-third remaining on their original two medications, one-third on two placebos but no active medication, and one-third on one placebo and one psychoactive drug. While there were significant changes in patient pathologies, the female trend was different from the male. Analyzing the data, the authors conclude that polypharmacy, especially in men, is often an inadequate form of treatment.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.